Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 5/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189095 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1187097 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1189524 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1187614 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1187197 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1187358 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1187088 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1188246 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1186782 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1189282 | 1.00 | KCNH2 (0.37) | KCNH2MEN1KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2008319-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | TPR, ROR1, CA3 | KCNH2 3391/4885MEN1 1342/4885KMT2A 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.